Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

NCT03293069 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT03293069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03293069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Lead sponsor
University Hospital, Lille
Phase
Phase 2/3
Overall status
Completed
Start date
January 30, 2019
Completion date
May 6, 2024
Enrollment
372 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis